What Evoke Pharma does

Evoke Pharma, Inc. is a specialty pharmaceutical company founded in 2007 and headquartered in Solana Beach, California, that develops and commercializes therapeutics for gastrointestinal diseases, with a single commercial product: GIMOTI (metoclopramide) nasal spray. GIMOTI is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis; it delivers metoclopramide via the nasal route, bypassing the gastrointestinal tract to provide more predictable absorption during gastroparesis flares or vomiting. The company commercializes GIMOTI exclusively in the United States through a partnership with EVERSANA Life Sciences, which provides sales, marketing, access and reimbursement, adherence, and product distribution services on Evoke's behalf.

Evoke generates revenue through net product sales of GIMOTI, with Q3 2025 net product sales of $4.3 million representing a 61% year-over-year increase, and a 2024 market projection of approximately $10.2 million in annual sales. A newly issued US patent extends GIMOTI's market exclusivity to November 2038, and the company has stated plans to expand its pipeline through in-licensing or acquisition of additional gastroenterology-focused products. The company was acquired by QOL Medical in December 2025 at $11.00 per share in cash (a 139.7% premium to its recent Nasdaq closing price) and is now a wholly owned subsidiary, with Evoke's common stock having ceased trading on Nasdaq on December 17, 2025. The company operates with a lean structure of 1-10 employees, relying on its EVERSANA partnership for end-to-end commercial execution in the US market.

Name

Evoke Pharma

Legal name

Evoke Pharma, Inc.

Website

https://evokepharma.com

Company type

Public

Founded year

2007

Operating status

Acquired

Headcount range

1–10 employees

Short description

Evoke Pharma is a specialty pharmaceutical company that develops and commercializes GIMOTI, the first and only FDA-approved non-oral (nasal spray) treatment for diabetic gastroparesis, distributed in the United States via its commercialization partner EVERSANA.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals — Gastrointestinal Therapeutics

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• Specialty pharmaceuticals
• Gastrointestinal therapeutics
• Nasal drug delivery
• Diabetic gastroparesis treatment
• Metoclopramide formulations

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Personnel, Operations, Technology or R&D

Revenue model

1. GIMOTI Product Sales: Evoke Pharma generates revenue through net product sales of GIMOTI (metoclopramide) nasal spray. Q3 2025 net product sales reached $4.3 million, representing a 61% year-over-year increase. The company was acquired by QOL Medical in late 2025 for $11.00 per share.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Evoke Pharma develops and commercializes GIMOTI, a metoclopramide nasal spray that is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The nasal route bypasses the gastrointestinal tract to provide more predictable drug absorption even during gastroparesis flares or vomiting, addressing a key gap left by oral metoclopramide approved since 1979. Evoke commercializes GIMOTI in the United States through a partnership with EVERSANA Life Sciences.

Product overview

Evoke Pharma is a specialty pharmaceutical company with a single core product: GIMOTI (metoclopramide) nasal spray. GIMOTI is the first and only FDA-approved non-oral treatment for diabetic gastroparesis, delivering the FDA-approved drug metoclopramide via nasal spray for more predictable absorption compared to oral administration. The company operates with a commercial partnership with EVERSANA Life Sciences for U.S. commercialization services and has plans to expand its pipeline through in-licensing or acquisition of additional gastroenterology-focused products.

Differentiator

Problem solved

Functional benefit

Brands

• GIMOTI: GIMOTI (metoclopramide) nasal spray is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis (DGP).

Products and services

• GIMOTI (metoclopramide) nasal spray GIMOTI is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It delivers metoclopramide through the nasal route, bypassing the gastrointestinal tract for more predictable absorption, and is also positioned to support patients on GLP-1 medications experiencing DGP symptoms.

Quantifiable outcome

• Healthcare cost savings of approximately $15,000 per patient within six months compared to oral metoclopramide
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• QOL MedicalcoreStrategic or Co-development Partner · 4 November 2025Evoke Pharma entered into a definitive agreement to be acquired by QOL Medical at $11.00 per share in cash, representing a 139.7% premium to its recent Nasdaq closing price. The transaction was approved by both boards and expected to close in Q4 2025 through a tender offer followed by a merger. The tender offer expired on December 15, 2025 with 67.63% of shares tendered, and the merger was consummated making Evoke a wholly owned subsidiary of QOL Medical.
• EVERSANA Life SciencescoreChannel Partner/ Reseller/ DistributorEvoke has an agreement with EVERSANA for the complete commercialization of GIMOTI in the United States. Through this partnership, Evoke leverages EVERSANA's suite of capabilities and experts to implement their commercial strategy. The collaboration offers seamless integrated advantage across sales, marketing, access and reimbursement services, adherence, product distribution, and other services.

Scale indicators7 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Salix Pharmaceuticals: Salix (now part of Bausch Health) is one of the largest US gastroenterology specialty pharmaceutical companies with a broad GI portfolio including treatments for IBS, bowel prep, and hepatic encephalopathy. Highly comparable business model of focused GI specialty drug commercialization, though at much larger scale than Evoke.

Direct peers

• Ironwood Pharmaceuticals: Ironwood commercializes LINZESS (linaclotide) for IBS-C and CIC, making it a direct GI specialty pharma peer. Both companies operate single-asset or focused-portfolio commercial models targeting gastroenterologists and primary care, with similar reliance on prescriber adoption and payer access.
• RedHill Biopharma: RedHill is a specialty pharma focused on gastrointestinal diseases, with commercial products for H. pylori, IBS, and gastroenteritis. Highly comparable as a small-cap GI specialty commercial-stage company, though RedHill operates across multiple assets rather than a single product.
• Ardelyx: Ardelyx commercializes IBSRELA (tenapanor) and XPHOZAH for hyperphosphatemia, both targeting GI and renal specialists. Comparable as a small-cap GI-focused specialty commercial pharma with similar single-asset dynamics and prescriber-focused commercial model.
• Phathom Pharmaceuticals: Phathom commercializes VOQUEZNA (vonoprazan) for H. pylori and erosive esophagitis. Directly comparable as a small-cap GI specialty commercial pharma with a novel mechanism product targeting gastroenterologists, with a similar prescriber-driven commercial model.
• Sebela Pharmaceuticals: Sebela is a private specialty pharmaceutical company with multiple GI and women's health products, including treatments for bowel prep and IBS. Comparable as a privately held GI specialty pharma with similar commercial scale and prescriber-focused business model.
• Aytu BioPharma: Aytu BioPharma is a small specialty pharmaceutical company commercializing products in pediatrics, respiratory, and GI. Relevant as a small-cap specialty pharma with GI exposure and similar commercial scale dynamics; Aytu's CCO Greg Pyszczymuka recently joined Evoke's board, signaling industry overlap.

Others

• QOL Medical: QOL Medical is the parent company that acquired Evoke Pharma in December 2025. Relevant as the strategic acquirer and now owner of GIMOTI; QOL focuses on rare and specialty diseases and is itself a small specialty pharma.

Regional players

• US WorldMeds: US WorldMeds is a privately held specialty pharma with a portfolio spanning gastroenterology, rare diseases, and neurology. Comparable as a privately held specialty commercial-stage pharma with GI exposure, though broader in scope.

Emerging players

• Napo Pharmaceuticals: Napo (now Jaguar Health) commercializes Mytesi (crofelemer) for HIV-related diarrhea and is developing treatments for GI-related conditions. Comparable as a small specialty GI pharma with a single primary commercial asset and similar prescriber-focused commercialization dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/evoke-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evoke Pharma